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Abstract
Background: Left ventricular assist devices (LVADs) are used as an advanced
therapy option for patients with stage D heart failure. These devices provide
mechanical unloading of the heart as either a bridge to transplant or recovery, or
as destination therapy. In patients with LVADs, there are emerging data on the use
of heart failure guideline-directed medical therapy (GDMT) to improve outcomes.
This review describes the current evidence available for the use of neurohormonal
blocking agents in patients with LVADs.
Methods: Articles were found using PubMed and web searches for heart failure
therapies/neurohormonal blockade and LVADs. Studies were included if they
evaluated the use of the heart failure therapies, either retrospectively or
prospectively.
Results: A total of 17 articles and 9 abstracts were reviewed. The totality of data
surrounding the use of GDMT neurohormonal blockade in patients with LVADs are
limited in nature. Much of the data are limited either by use of surrogate outcomes,
single center evaluations, and/or small sample sizes. However, the evidence does
support clinical benefit with associated mechanistic plausibility. More research is
needed to understand appropriate patient selection and means to optimize these
therapies in the LVAD population.
Conclusion: Combined neurohormonal blockade appears to reduce morbidity and
mortality in patients with LVAD implants.
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Background
The use of mechanical circulatory support with a left ventricular assist device
(LVAD) has increased as a treatment option for patients with stage D heart failure
(HF).1 A limited donor pool for orthotopic heart transplantation (OHTx) in
conjunction with advancements in LVAD technology have fueled this growth. The
available LVADs in the United States have two Food and Drug Administration
approved indications for implantation: 1) bridge to transplantation for patients who
are candidates for OHTx and at risk of death from stage D HF; or 2) destination
therapy for patients who are not candidates for OHTx.2 A review of the devices’
approval history and mechanics are beyond the scope of this article.
According to the 2017 American College of Cardiology /American Heart
Association HF guideline updates, LVAD implantation is indicated for eligible
patients who have stage D HF with reduced ejection fraction (EF) (HFrEF).3
Despite these recommendations, there are inherit risks associated with placement
of an LVAD due to the invasive nature of the procedure and device; thus, patient
selection requires a multidisciplinary approach. After placement of the LVAD, the
patient must have extensive education on what activities are permissible and how
to manage the device. Management considerations for the LVAD patient include
addition of anti-thrombotic therapy, driveline maintenance, and alarm-awareness.
However, what is less defined is the role and use of guideline-directed medical
therapy (GDMT) for HF. Limited data are available to guide the use of HF therapy
following implantation, and the 2020 International Society of Heart and Lung
Transplant (ISHLT) mechanical circulatory support (MCS) guidelines only briefly
outline recommendations based on these data.1 Therefore, the purpose of this
review is to evaluate the evidence for use of HF GDMT in patients with a durable
LVAD. Additionally, we aim to provide treatment recommendations for optimizing
GDMT in this patient population.

Methods
Medline and Google Scholar were searched from January 2000 to February 2021
using the term “ventricular assist device” or “LVAD” with each of the following
terms: “neurohormonal blockade,” “heart failure therapy,” “guideline-directed
medical therapy,” “beta blocker,” “beta blockade,” “angiotensin converting
enzyme,” “angiotensin receptor blockers,” “ACE,” “ARB,” “RAAS,” “sacubitrilvalsartan,” “ARNi,” “mineralocorticoid receptor antagonist,” “aldosterone
antagonist,” and “MRA.” Retrospective and prospective studies were included in
abstract and full article format. Studies with animal subjects, written in a language
other than English, or with only in vitro or ex vivo data were excluded, as were
studies with temporary mechanical circulatory support. Additionally, in the instance
that studies were in both published abstract and article format, only the article was
included.
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Results
Guideline-Directed Medical Therapies
The mechanism behind the combined use of device support and medication is to
unload the left ventricle (LV) mechanically and via neurohormonal pathways, such
as the renin-angiotensin-aldosterone system (RAAS), to help with myocardial
recovery.4 In this review article, neurohormonal blockade (NHB) was considered to
be one or more of the following medication classes which are listed as class I level
of evidence A recommendations for chronic HFrEF: angiotensin-converting
enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), angiotensin
receptor-neprilysin inhibitor (ARNi), beta blocker (BB), and mineralocorticoid
receptor antagonist (MRA).3
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor
Blockers
In patients with LVADs, the device supports the damaged heart by mechanically
unloading the ventricular volume; however, the force of the unloading can
contribute to myocardial stiffness. Three articles and one published abstract
evaluating the myocardial response to ACEi and ARB therapy in LVAD patients
are included in this review.5-8
Klotz et al. have investigated the use of ACEi therapy to reduce this sequela in
patients supported with HeartMate VE LVADs (Abbott, Chicago, IL).5,6 In the
authors’ first study, heart samples were collected during implantation and postexplantation of the LVAD in 22 patients. The 7 subjects in the ACEi group received
enalapril, captopril, or lisinopril at approximately 30 days post-implantation until the
device was explanted for transplant. In all patients, angiotensin I and II
concentrations were higher pre- versus post-LVAD implantation (p<0.05).
However, at explantation, angiotensin II content was significantly lower in patients
receiving ACEi therapy compared to those not on ACEi (81 fmol/g ±7 vs. 262
fmol/g ±41, p <0.05). Additionally, the collagen content, LV mass, and myocardial
stiffness were significantly decreased with ACEi use (p<0.05). These findings
suggest reverse remodeling does occur in patients on ACEi therapy after LVAD
implantation.5 Based on the aforementioned results, the authors sought to
investigate the effects of ACEi therapy on renin, aldosterone, and norepinephrine
in 20 HeartMate VE LVAD patients. At implantation, patients in both groups had
renin levels that were 100-fold higher than normal, and resultant cardiac
angiotensinogen was diminished. In those not prescribed ACEi post-implant,
cardiac aldosterone and renin decreased (p<0.006 and p<0.001, respectively);
whereas, norepinephrine increased by approximately seven-fold (p=0.004). ACEi
patients did not experience these effects; their aldosterone and renin remained
elevated, and norepinephrine did not increase. Thus, ACEi therapy helps to
prevent the activation of the sympathetic nervous system in these patients and
prevent cardiac fibrosis.6
These studies demonstrated a biochemical basis to warrant further evaluation of
the clinical effects of neurohormonal modulation in patients with an LVAD (Figure
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1). Their small sample sizes, the use of laboratory parameters instead of clinical
outcomes, and the low proportion (20%) of female patients, limit the applicability of
both of these studies. Additionally, the HeartMate VE is a first generation, pulsatile
LVAD that is now obsolete. Thus, comparisions are not applicable to to HeartMate
3 devices and HVADs, which are third generation devices with continuous
centrifugal flow and electromagnetic technology.7

Figure 1. Changes in the cardiac renin-angiotensin-aldosterone system (RAAS) with and without angiotensinconverting enzyme inhibitor after the implantation of a left ventricular assist device (LVAD).
In a retrospective study of 307 patients with either a HeartMate IITM (HMII, Abbott,
Chicago, IL) or a HeartWareTM ventricular assist device (HVAD, Medtronic, Dublin
Ireland), the use of NHB therapy and its impact on mortality was evaluated.8 Of the
patients included, 76.5% were male and 63.5% were Caucasian, with a mean age
of 60 years. At 12 months, 30.9% of patients who were alive with an implant were
on ACEi or ARB therapy alone or combined with other therapy. ACEi/ARB therapy
was associated with decreased mortality when death secondary to neurological
conditions, HF, and respiratory failure was analyzed together (HR 0.38 [0.16-0.94],
p=0.037). The use of ACEi or ARB therapy in the time-dependent evaluation of
mortality post-implant was associated with a 50% decrease in mortality (HR 0.50
[0.29-0.86], p=0.01). Significant differences in patients in the ACEi/ARB group
compared to the no-ACEi/ARB group included more African-American patients
(33.3% vs. 17.3%, p<0.01), younger patients (57 years vs. 61 years, p<0.01), and
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more non-ischemic patients (50.8% vs. 36.4%, p=0.03). Although limited by its
retrospective nature, this larger study of more than 300 patients suggests a
potential mortality benefit of continued ACEi or ARB use after implantation of an
LVAD.
Reduction in mortality was further explored in a retrospective analysis of the ISHLT
Mechanically Assisted Circulatory Support (IMACS) registry, including 11,494
patients who were implanted with a continuous-flow LVAD (CF-LVAD) and were
alive at 3 months post-implant.9 Of the patients included, the 50% who were
prescribed an ACEi/ARB were compared to propensity score-matched patients
without any RAAS blockade. The Cox proportional hazards survival analysis used
ACEi as an independent variable and demonstrated an association with survival
(HR 0.79 [0.69-0.90], p<0.001). The authors concluded that in patients who
tolerate the addition of an ACEi or ARB to their medication regimen, a mortality
benefit might be incurred at 12 months after LVAD implantation. This study
confirmed the findings of the previous studies in a large outcome and populationbased manner. However, given the data are from a registry, it is limited by lack of
treatment information, inability to account for confounders, as well as potential
under-reporting of the outcomes.
An additional benefit of angiotensin II inhibition is a reduced risk for the
development of gastrointestinal bleeding (GIB) secondary to arteriovenous
malformations (AVM)—a common complication after LVAD implantation. Four
articles addressing the gastrointestinal protective effects of angiotensin II inhibition
were included in this review.10-13 A retrospective analysis was completed that
compared 100 patients with either a HMII or HVAD on ACEi or ARB therapy to 31
patients that did not receive either medication. Twenty four percent of the patients
in the ACEi/ARB group reported GIB as compared to 48% in the no ACEi/ARB
group (OR 0.29, [0.29-0.72]).10 The results were further delineated into patients
experiencing GIB secondary to AVM. Once again, the ACEi/ARB group had a
lower incidence (9%) when compared to the no-ACEi/ARB group (29%, OR 0.23
[0.07-0.71]). Because this study was conducted at a single center and was limited
by its retrospective nature, it is mostly hypothesis generating.
Similar results were reported in a study of 111 CF-LVAD patients when an ACEi or
ARB was initiated within 30 days post-implantation.11 The patients on ACEi or ARB
therapy experienced a 57% reduction in overall GIB rates (HR 0.43, [0.19-0.97],
p=0.042) and a 63% reduction in AVM-related GIB (HR 0.37, [0.16-0.84],
p=0.017). The authors found the reduction in GIB was most likely to be doserelated with a minimum threshold of an ACEi equivalent of 5 mg of lisinopril daily.
The authors did not elaborate in this single center study on other factors that can
affect GIB, including other medication therapy that could perpetuate or protect
against GIB.
A retrospective analysis of 377 patients with HVAD or HMII LVADs categorized
patients according to the number of GIB experienced per year (no bleed, 1 bleed,
1-3 bleeds, >3 bleeds).12 Results demonstrated that patients with more GIB were
less likely to be on an ACEi or ARB compared to patients with no GIB (51% v 79%,
p<0.0001). When adjusted for age, sex, Interagency Registry for Mechanically

The VAD Journal: Heart Failure Therapy in LVAD Patients

Page 5 of 16

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Assisted Circulatory Support (INTERMACS) profile, bridge-to-transplant status,
creatinine, and body mass index, ACEi/ARB therapy was associated with a 67%
reduction in the incidence of GIB (95% CI 0.15-0.71, p=0.005).
A meta-analysis of the previous three studies10-12 determined the relationship
between angiotensin II antagonism and GIB in LVADs.13 The pooled analysis of
the CF-LVAD patients (n=619) revealed a significant reduction in GIB in patients
receiving ACEi/ARB therapy (OR 0.35, 95% CI 0.22-0.56, I2=0%, p<0.001).
However, there was not a significant reduction in AVM-related GIB (OR 0.46, 95%
CI 0.19-0.17, I2=51%, p=0.07). No publication bias assessment was able to be
performed due to the small number of studies included.
The results from these single-center studies suggest ACEi/ARB therapy proves a
gastro-protective effect in LVAD patients in addition to the proposed mortality
benefit.
Angiotensin Receptor-Neprilysin Inhibitor
Evidence for the use of sacubitril-valsartan in LVAD recipients is limited to date; our
literature review found only four published abstracts and one article.14-18
In a study of 10 patients who were initiated on sacubitril-valsartan, 6 patients were
able to tolerate the maximum dose of 97-103 mg.14 The results revealed that ARNi
therapy was safe, with potassium (mEq/L) and creatinine (mg/dl) differences at
baseline and 3 months of 4.2 ±0.3 versus 4.4 ±0.3 and 0.84 ±0.2 versus 0.85
±0.19, respectively.
In a separate study, 12 HMII patients on sacubitril-valsartan therapy were
compared to 12 patients on other anti-hypertensive therapy.15 Those on sacubitrilvalsartan therapy had an average mean arterial pressure (MAP) reduction of 20
mmHg compared to a 12 mmHg reduction in patients on standard antihypertensives. Additionally, the authors found a decreased rate of stroke and readmissions compared to standard of care without an increase in adverse effects,
although no numerical details were provided to show the extent of these outcomes.
A single-center, retrospective case series of 10 patients prescribed ARNi therapy
post-implant reported a significant reduction in MAP (20.0 ± 14.0 mmHg, p=0.002)
and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) (2,929 pg/mL to
1,530 pg/mL, p=0.36).16 This positive effect was not accompanied by either an
increase in serum creatinine or potassium in most patients, with only one report of
hyperkalemia that required discontinuation of sacubitril-valsartan.
Similar changes were reported at a center in which 30 LVAD patients prescribed
sacubitril-valsartan experienced a significant decrease in NT-proBNP at 6 months
(1,082 pg/mL to 651 pg/mL, p=0.013).17 At 6 months 41% of patients were
prescribed 24/26 mg, 27% at 49/51 mg, and 32% at 97/103 mg. These data
support the safe and effective use of sacubitril-valsartan as an anti-hypertensive
medication, but do not elaborate on heart failure morbidity or mortality outcomes.
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A single center evaluated 20 LVAD patients pre- and post-ARNi initiation to
determine effects on MAP and HF morbidity.18 At 3 months post-initiation, MAPs
decreased from 92 ±24 to 75 ±19 mmHg (p<0.001), and the New York Heart
Association Functional Class improved significantly from 2.6 ±0.8 to 1.6 ±0.7
(p<0.001). Additionally, the authors found a reduction in calcium channel blocker
and diuretic dose. Six patients did not tolerate the sacubitril-valsartan and therapy
was discontinued.
Initial data for sacubitril-valsartan suggest a physiological and clinical benefit with
minimal patients experiencing adverse effects. It is important to note that the
patients on ARNi therapy in these studies were stable at baseline. In addition, the
small number of patients included, the single center nature, and the lack of baseline
demographic information provided in the abstracts limit the ability to apply these
data to other patients with LVADs.
Beta Blockers
Despite the accumulating experience with NHB as a therapeutic intervention to
improve outcomes for patients with LVADs, the evidence for BB therapy alone is
limited to 1 article and 3 published abstracts.19-22
A retrospective study from Japan examined factors predictive of LV reverse
remodeling (LVRR) in 60 patients with non-ischemic dilated cardiomyopathy who
received either pulsatile or CF-LVAD support as a bridge to recovery.19 Patients
were treated pre-operatively with standard medical therapy that consisted of BB
(carvedilol or bisoprolol), ACEi, ARBs, and MRA as tolerated. The endpoint of
LVRR was defined as a left ventricular ejection fraction (LVEF) of ≥35% at 6
months post-LVAD or explantation of LVAD within 6 months. Overall, 27% of the
study cohort achieved LVRR, and 10% were explanted. The authors found that
lower titrations of pre-operative BB use and pulsatile flow LVADs were each
significantly associated with LVRR during LVAD support. Furthermore, a dosedependent relationship with BB treatment was apparent on univariate analysis
(maximum dose of BB, 2.7 ± 3.5 vs. 9.9 ± 6.4 mg/day in carvedilol equivalents [5
mg bisoprolol equivalent to 20 mg carvedilol]; p=0.015). The authors used
multivariate analysis to identify a threshold of a cumulative BB dose of <1.6 gm
(p=0.005). The authors concluded that the impact of post-operative BB use is most
effective in patients who were not maximized on BB therapy pre-operatively. Doses
of BB were well described in this study, although the information provided regarding
pulsatile flow LVADs has limited applicability in the current era of CF devices.
Other retrospective studies of BB use in the LVAD population have been reported
in abstract form.20-21
A review of 98 patients with CF-LVAD showed that BB use (n=72) compared to
non-use (n=26) was associated with lower NT-proBNP concentrations at 6 and 12
months post-LVAD implant without an increase in hospitalizations.20 There was a
trend toward fewer deaths in the BB group (6% vs. 15%). Notably, approximately
half the patients in this study had greater than moderate right ventricular
dysfunction.
The VAD Journal: Heart Failure Therapy in LVAD Patients
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Another study of CF-LVAD patients evaluated differences in outcomes between
carvedilol and metoprolol. Among 220 patients, 85% received a BB at the time of
the first outpatient visit.21 The authors reported a lower risk for pump thrombosis
with carvedilol (p = 0.04), despite a trend toward more GIB as compared to
metoprolol (p=0.08).
Finally, a study of 159 patients demonstrated that BB use compared to non-use
was independently associated with survival in patients with a CF-LVAD (HR 0.33,
95% CI 0.15-0.71; p = 0.006).22
Limitations of each of these studies include the retrospective design and relatively
small patient cohorts. Decisions about BB use, agent selection, and dose were left
to prescriber discretion in each study. Nonetheless, signals of improved outcome
with BB use for the CF-LVAD patient population were evident and support modern
registry data, which illustrates a beneficial role for NHB in these patients.1 The
available data indicate the use of one of the three BBs with an indication in chronic
HF at maximally tolerated doses leads to ventricular recovery and improved
survival. Optimal dosing and effects on right ventricular activity still need to be
elucidated with further research.
Mineralocorticoid Receptor Antagonists
To date, two abstracts have been published evaluating MRA use in patients with
LVADs. However, the results of abstracts indicate conflicting results with regards to
cardiac recovery. In a one abstract of 27 patients, the 14 patients who were
prescribed MRAs had a greater improvement in LVEF compared to those who were
not (18 ±2 to 37 ±4 vs. 20 ±3 to 27 ±4%, p<0.01).23 In the MRA group, 93% were
prescribed BB and 85% received an ACEi in comparison to 100% and 62% in the
non-MRA group. This study is a post-hoc analysis of a prospective study at a single
center, limiting the interpretation of the statistical analysis.
Brinkley et al. included 2,670 patients prescribed MRAs in their analysis of RAASmodulating medications.9 Similar to the ACEi/ARB arm, survival was improved in
the MRA versus no RAAS (p=0.03). However, when results were adjusted for
known predictors of survival in the Cox proportional hazards analysis, MRA use
was not associated with improved survival (HR 0.94 [95% CI 1.02-1.49], p=0.33).
The authors do not include further information on doses received by patients, length
of time on therapy, or differences in other therapies between groups.

Combined Neurohormonal Blockade
Eight articles have evaluated the use of combined NHB in patients with durable
LVADs and are included in this review.24-31 The majority of these articles focus on
the intent of device explantation.24-29 In patients who were evaluated for bridge to
recovery with optimization of device support and medication regimens, there are
inconsistencies in the agents used and the duration of therapy (Table 1).
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The most well-defined medication regimens were described by Birks et al. in
patients with HeartMate ITM (Abbott, Chicago, IL), and later, HMII devices.25,26,29
These subjects prospectively underwent two stages of medication therapy in the
Harefield Protocol.25,26 The patients included in these studies all had non-ischemic
cardiomyopathy supported with HeartMateTM devices and tended to be younger
males with a shorter duration of HF prior to LVAD. The first stage of the Harefield
Protocol for medication titration is well-described and indicates aggressive uptitration of NHB early post-implant can be safe and leads to improvement in cardiac
parameters. Stage one consisted of initiation of lisinopril, carvedilol, spironolactone,
and losartan. After inotropic wean post-implant, these four medications were uptitrated to maximally tolerated doses. Stage two started after patients maintained
the maximal regression in LV end diastolic diameter (LVEDD) for two weeks. At this
point, patients were converted from carvedilol therapy to bisoprolol, and clenbuterol
(a beta2 adrenergic agonist) was added at 40 mcg twice daily and titrated to a dose
of 700 mcg three times daily. Explantation was performed in patients who
maintained LVEF >45% and LVEDD <60 mm, along with other cardiac parameters
(Table 1). With this protocol the explant rate was 73% in HeartMate I devices with a
mean duration of support of 320 ± 186 days, and 60% in HMII devices with a mean
duration of support of 286 ±97 days.25,26
In the largest study conducted by Birks et al. with 36 HMII patients, 19 total patients
had their LVAD removed under the study protocol.29 The following medications
were initiated after inotropes were weaned off: lisinopril (goal 20 mg twice daily);
carvedilol (goal 50 mg twice daily); spironolactone (goal 25 mg daily); digoxin (goal
125 mcg daily); and losartan (150 mg daily). Medications were titrated to achieve a
MAP >60 mmHg with no upper limit. Phase two of the previously mentioned
Harefield Protocol was not used in this study. Sixteen (44%) of patients met the
primary endpoint of explant within 18 months with freedom from mechanical
circulatory support and heart transplantation at one year after explant (p<0.01).
Lower preoperative serum creatinine was associated with a higher chance of
recovery in univariate analysis (p<0.05), which the authors attributed to a potentially
greater ability to tolerate higher doses of NHB.
Other studies have analyzed clinical outcomes in patients without LV recovery to
determine the potential morbidity and mortality benefits from NHB in LVAD patients.
In the retrospective cohort analysis of INTERMACS, outcomes including survival
and quality of life were evaluated in patients who received NHB.30 Among 12,144
patients who survived 6 months post-LVAD placement, 2,742 (22.6%) received a
BB with an ACEi or an ARB; 2,359 (19.4%) received a BB alone; 1,967 (16.2%)
received triple therapy with a BB, ACEi or ARB, and MRA; and 1,200 (9.8%)
received a BB and MRA. For comparison, 1,725 (14.2%) of the cohort did not
receive any NHB. Of note, medications in this group included any combination of
the following: digoxin, amiodarone, calcium channel blockers, hydralazine, and
phosphodiesterase inhibitors. Compared to patients who did not receive NHB, the
triple therapy group had significantly greater survival (68.5%; 95% CI, 65.2%-72%
vs. 53.9%; 95% CI, 49.1%-59.4%, p<0.0001). When compared to the other
medication groups, triple therapy was also associated with significantly greater
odds of survival (HR 0.34; 95% CI, 0.28-0.41; p<0.001). All combinations of NHB
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improved survival with the exception of MRA monotherapy (adjusted HR 0.88; 95%
CI, 0.7-1.1, p=0.3). The overall association between NHB and outcome was
consistent regardless of LVAD indication. Quality of life estimates via the Kansas
City Cardiomyopathy Questionnaire score and 6-minute walk distance also
improved when NHB was compared to no NHB. Furthermore, biomarkers including
NT-proBNP and average creatinine were each lower in the triple therapy versus no
NHB groups. This study represents a large population of patients and provides
insight into optimal combinations of NHB with triple therapy. No data are provided
on dosing to help guide optimal titration strategies of the medications.
A smaller, single-center retrospective study was conducted in adult patients with
HMIIs and either ischemic or dilated cardiomyopathy.31 Patients were categorized
as having received NHB (n=31) versus those who had received no NHB (n=33).
Baseline demographics did not vary between groups. Within the NHB group, 20
(64.5%) patients received an ACEi or ARB, 26 (83.9%) received a BB, and 2
(6.5%) received an MRA. Combination therapy groups consisted of 19 (61.3%)
patients prescribed an ACEi/ARB plus BB, and 2 (6.5%) patients prescribed
ACEi/ARB plus BB plus MRA. NHB was initiated at the discretion of the treating
cardiologist to maintain a mean blood pressure below 80 mmHg and a heart rate
below 100 beats per minute. On average, patients in the NHB group achieved daily
doses of lisinopril (10 mg), enalapril (7.5 mg), or quinapril (15 mg) for ACEi therapy;
candesartan (4 mg), telmisartan (40 mg), or losartan (25 mg) for ARB therapy;
carvedilol (25 mg), metoprolol (75 mg), and atenolol (50 mg) for BB therapy; and
spironolactone (25 mg) for MRA therapy. At 6 months, the percent change in LVEF,
LVEDD index, LV index mass, and NT-proBNP was significant in the NHB group
(p=0.025, p=0.017, p=0.031, and p=0.011, respectively). These differences were
not seen in the no NHB group. Regarding quality of life outcomes, overall New York
Heart Association classification was significantly improved in the NHB compared to
non-NHB group at 3 and 6 months (p=0.021 and p=0.024, respectively). No
numerical data were provided on the change from baseline in any of these
parameters. Additionally, in patients who completed the 6-minute walking distance
test, those in the NHB group (n=15) experienced a statistically greater improvement
than the non-NHB patients (n=13) at 3 months (70.3 ±48.4 m vs. 24.4 ±48.8 m,
p=0.019) and 6 months (146 ±58.9 vs. 49.4 ±54.6, p=0.0007) post-implant. The
composite outcome of cardiovascular death or hospitalization for HF was
significantly less in the NHB group (0% vs. 18.2%, p=0.013). There was no
significant difference in all-cause mortality. Although limited by the number of
patients included and the non-randomized nature of the patient allocation, this small
study indicates improvement in HF parameters, morbidity, and mortality in patients
with LVADs prescribed NHB.

Future Directions
Despite the promising role for NHB in patients with LVADs, current evidence is
limited by the observational nature of the studies, small sample sizes, and use of
different LVAD models. Additionally, many of the studies lack details regarding
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medication dose, adherence, and reasons for initiation or discontinuation.
However, a synergistic effect between pharmacologic therapy and mechanical
unloading leading to improvements in survival, quality of life, and biomarkers was
evident. With the majority of data originating from retrospective analyses,
prospective trials will need to be conducted in order to corroborate the current
body of literature.
There is a gap in the literature on the ideal time to start these medications and the
doses that are adequate to achieve morbidity and mortality outcomes. Based on
the studies in patients undergoing rigorous protocols for myocardial recovery and
LVAD explantation, patients can tolerate early initiation during their index implant
hospitalization, as well as moderate to high doses of NHB. The use of sacubitrilvalsartan therapy shows promise in reducing MAPs and NT-proBNP without
increased harm from adverse effects. Initial outcomes data indicate improved
morbidity outcomes with improvements in functional classification.

Conclusions
There is a paucity of data regarding the use of HF therapies in patients with
LVADs. In practice, the use of GDMT post-LVAD implant has largely focused on
blood pressure management, however, current evidence suggests the use of NHB
may increase device explantation rates, increase functional capacity, and
decrease mortality. The optimal combination of GDMT appears to be triple therapy
with an ACEi or ARB, BB, and MRA. The data suggest MRA use alone does not
have an impact on mortality, unlike ACEi or ARB and BB therapy. Thus, HF
medications in LVAD patients should first focus on ACEi or ARB and BB initiation
prior to MRA therapy. If patients are able to tolerate doses of sacubitril-valsartan
without hypotension, hyperkalemia, or serum creatinine increases, it may be
reasonable to substitute ARNi therapy for ACEi/ARB in the triple therapy
combination described above. As destination therapy becomes a more common
indication for device implants and more patients wait for a heart transplant,
optimizing these therapies will be critical in the support of patients with LVADs.32,33
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